InsidersTradesSigma
Total declarations
Company
▲ Purchases (13 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by THEUER CHARLES, Chairman & CEO. Insider active across 1 companies, notably Tracon Pharmaceuticals, Inc.. In total, 13 reports have been published. Total volume traded: €86k. The latest transaction was filed on 9 May 2022 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations13 total
€17,50910,000 shares@ €1.750920.5% of flow
Common Stock
SEC:0001209191-22-028188:0·
Ideal exit: 3 Feb 2023 (T+270)
€4,6732,500 shares@ €1.86915.5% of flow
Common Stock
SEC:0001209191-22-027975:0·
Ideal exit: 31 Jan 2023 (T+270)
€9,3815,000 shares@ €1.876311.0% of flow
Common Stock
SEC:0001209191-22-026562:0·
Ideal exit: 24 Jan 2023 (T+270)
€9,5524,500 shares@ €2.122711.2% of flow
Common Stock
SEC:0001209191-22-025471:0·
Ideal exit: 16 Jan 2023 (T+270)
€4,6022,000 shares@ €2.3015.4% of flow
Common Stock
SEC:0001209191-22-024070:0·
Ideal exit: 3 Jan 2023 (T+270)
€9,6764,000 shares@ €2.41911.3% of flow
Common Stock
SEC:0001209191-22-021876:0·
Ideal exit: 25 Dec 2022 (T+270)
€2,6621,200 shares@ €2.21863.1% of flow
Common Stock
SEC:0001209191-22-020678:0·
Ideal exit: 16 Dec 2022 (T+270)
€1,732681 shares@ €2.543912.6% of flow
Common Stock
SEC:0001209191-21-066096·
Ideal exit: 15 Aug 2022 (T+270)
€1,732681 shares@ €2.54392.0% of flow
Common Stock
SEC:0001209191-21-066096:0·
Ideal exit: 15 Aug 2022 (T+270)
€2,9511,000 shares@ €2.95121.5% of flow
Common Stock
SEC:0001209191-21-063520·
Ideal exit: 2 Aug 2022 (T+270)
€2,9511,000 shares@ €2.9513.4% of flow
Common Stock
SEC:0001209191-21-063520:0·
Ideal exit: 2 Aug 2022 (T+270)
€9,0663,000 shares@ €3.022165.9% of flow
Common Stock
SEC:0001209191-21-052132·
Ideal exit: 13 May 2022 (T+270)
€9,0663,000 shares@ €3.022110.6% of flow
Common Stock
SEC:0001209191-21-052132:0·
Ideal exit: 13 May 2022 (T+270)
13 of 13 declarations
About THEUER CHARLES
Charles Theuer is the Chairman and CEO of Tracon Pharmaceuticals, Inc. He leads the company in the development of innovative cancer treatments. Under his leadership, Tracon aims to improve patient outcomes through targeted therapies. Charles Theuer has extensive experience in the pharmaceutical sector, contributing to the company's strategy and vision.
